Determining RBE for development of lung fibrosis induced by fractionated irradiation with carbon ions utilizing fibrosis index and high-LET BED model.
BED, biologically effective dose
Biologically effective dose (BED)
CPFE, combined pulmonary fibrosis and emphysema syndrome
CT, computed tomography
Carbon ion radiotherapy (CIRT)
FI, fibrosis index
Fractionation
HU, Hounsfield unit
High-linear energy transfer (high-LET)
LET, linear energy transfer
LQ model, linear quadratic model
Lung fibrosis
NSCLC, non-small cell lung cancer
Normal tissue response
PMMA, Polymethylmethacrylat
RBE, relative biological effectiveness
RILF, Radiation-induced lung fibrosis
RP, radiation pneumonitis
Relative biological effectiveness (RBE)
SBRT or SABR, hypofractionated stereotactic body or ablative radiation therapy
V5, volume of lung receiving ≥5 Gy (RBE)
α/β, alpha/beta ratio
Journal
Clinical and translational radiation oncology
ISSN: 2405-6308
Titre abrégé: Clin Transl Radiat Oncol
Pays: Ireland
ID NLM: 101713416
Informations de publication
Date de publication:
Jan 2019
Jan 2019
Historique:
received:
31
10
2018
accepted:
31
10
2018
entrez:
5
12
2018
pubmed:
5
12
2018
medline:
5
12
2018
Statut:
epublish
Résumé
Carbon ion radiotherapy (CIRT) with raster scanning technology is a promising treatment for lung cancer and thoracic malignancies. Determining normal tissue tolerance of organs at risk is of utmost importance for the success of CIRT. Here we report the relative biological effectiveness (RBE) of CIRT as a function of dose and fractionation for development of pulmonary fibrosis using well established fibrosis index (FI) model. Dose series of fractionated clinical quality CIRT versus conventional photon irradiation to the whole thorax were compared in C57BL6 mice. Quantitative assessment of pulmonary fibrosis was performed by applying the FI to computed tomography (CT) data acquired 24-weeks post irradiation. RBE was calculated as the ratio of photon to CIRT dose required for the same level of FI. Further RBE predictions were performed using the derived equation from high-linear energy transfer biologically effective dose (high-LET BED) model. The averaged lung fibrosis RBE of 5-fraction CIRT schedule was determined as 2.75 ± 0.55. The RBE estimate at the half maximum effective dose (RBE This is the first report of RBE estimation for CIRT with the endpoint of pulmonary fibrosis
Sections du résumé
BACKGROUND AND PURPOSES
OBJECTIVE
Carbon ion radiotherapy (CIRT) with raster scanning technology is a promising treatment for lung cancer and thoracic malignancies. Determining normal tissue tolerance of organs at risk is of utmost importance for the success of CIRT. Here we report the relative biological effectiveness (RBE) of CIRT as a function of dose and fractionation for development of pulmonary fibrosis using well established fibrosis index (FI) model.
MATERIALS AND METHODS
METHODS
Dose series of fractionated clinical quality CIRT versus conventional photon irradiation to the whole thorax were compared in C57BL6 mice. Quantitative assessment of pulmonary fibrosis was performed by applying the FI to computed tomography (CT) data acquired 24-weeks post irradiation. RBE was calculated as the ratio of photon to CIRT dose required for the same level of FI. Further RBE predictions were performed using the derived equation from high-linear energy transfer biologically effective dose (high-LET BED) model.
RESULTS
RESULTS
The averaged lung fibrosis RBE of 5-fraction CIRT schedule was determined as 2.75 ± 0.55. The RBE estimate at the half maximum effective dose (RBE
CONCLUSION
CONCLUSIONS
This is the first report of RBE estimation for CIRT with the endpoint of pulmonary fibrosis
Identifiants
pubmed: 30511024
doi: 10.1016/j.ctro.2018.10.005
pii: S2405-6308(18)30096-X
pmc: PMC6257927
doi:
Types de publication
Journal Article
Langues
eng
Pagination
25-32Références
Radiat Oncol. 2018 Jan 05;13(1):1
pubmed: 29304828
Exp Ther Med. 2013 Mar;5(3):771-776
pubmed: 23407465
Cancer Treat Rev. 2008 May;34(3):259-67
pubmed: 18226466
BMC Cancer. 2015 Mar 28;15:192
pubmed: 25886271
Int J Radiat Oncol Biol Phys. 2016 May 1;95(1):112-9
pubmed: 26254681
Semin Radiat Oncol. 2010 Jul;20(3):201-7
pubmed: 20685583
Radiat Oncol. 2017 Dec 29;12(1):208
pubmed: 29287602
Radiother Oncol. 2003 Oct;69(1):11-9
pubmed: 14597352
Clin Oncol (R Coll Radiol). 2001;13(2):71-81
pubmed: 11373882
Int J Radiat Oncol Biol Phys. 1987 Sep;13(9):1271-81
pubmed: 3305446
Oncotarget. 2016 Aug 30;7(35):56676-56689
pubmed: 27494855
J Thorac Oncol. 2007 Oct;2(10):916-26
pubmed: 17909354
Cancer. 2015 Apr 15;121(8):1321-7
pubmed: 25641119
Lancet Oncol. 2015 Feb;16(2):e93-e100
pubmed: 25638685
J Clin Oncol. 2007 Mar 10;25(8):953-64
pubmed: 17350944
Nat Rev Cancer. 2016 Apr;16(4):234-49
pubmed: 27009394
Semin Radiat Oncol. 2006 Oct;16(4):249-59
pubmed: 17010908
Int J Radiat Oncol Biol Phys. 1999 Feb 1;43(3):639-45
pubmed: 10078651
Clin Radiol. 2013 Jun;68(6):e275-90
pubmed: 23473474
Int J Radiat Oncol Biol Phys. 2003 Mar 15;55(4):861-6
pubmed: 12605963
Br J Radiol. 2006 Mar;79(939):254-7
pubmed: 16498040
J Radiat Res. 2007;48 Suppl A:A1-A13
pubmed: 17513896
Int J Radiat Oncol Biol Phys. 2013 Dec 1;87(5):1141-7
pubmed: 24113054
Phys Med Biol. 2017 Dec 19;63(1):01TR02
pubmed: 28976361
Int J Radiat Biol. 2007 Jan;83(1):27-39
pubmed: 17357437
J Exp Med. 2005 Mar 21;201(6):925-35
pubmed: 15781583
Radiat Oncol. 2017 May 30;12(1):91
pubmed: 28558766
J Radiat Res. 2007;48 Suppl A:A87-95
pubmed: 17513904
Acta Oncol. 2013 Oct;52(7):1272-86
pubmed: 23964656
Mol Cell Proteomics. 2017 May;16(5):855-872
pubmed: 28302921
Strahlenther Onkol. 1999 Jun;175 Suppl 2:39-43
pubmed: 10394395
Br J Radiol. 2016 Jul;89(1063):20160116
pubmed: 27146168
J Clin Oncol. 1995 Oct;13(10):2606-12
pubmed: 7595714
Radiother Oncol. 2010 Apr;95(1):3-22
pubmed: 20185186
Int J Radiat Oncol Biol Phys. 2006 Mar 15;64(4):1100-5
pubmed: 16373082
Int J Radiat Oncol Biol Phys. 1982 Nov;8(11):1981-97
pubmed: 6759484
Cancer Res. 2005 Aug 1;65(15):6509-11
pubmed: 16061627
Int J Radiat Biol. 1992 Aug;62(2):249-62
pubmed: 1355519
Lung Cancer. 2009 Apr;64(1):45-50
pubmed: 18762351
J Radiat Res. 2017 Sep 1;58(5):761-764
pubmed: 28992088
Radiother Oncol. 1995 Sep;36(3):211-7
pubmed: 8532908
Acta Oncol. 2015;54(9):1623-30
pubmed: 26271798
Int J Radiat Oncol Biol Phys. 2007 Mar 1;67(3):750-8
pubmed: 17293232
J Thorac Oncol. 2017 Apr;12(4):673-680
pubmed: 28007628
Int J Radiat Oncol Biol Phys. 2003 Jun 1;56(2):360-6
pubmed: 12738310
Radiat Oncol. 2017 Nov 7;12(1):172
pubmed: 29116014